Reduction of Coronavirus Burden With Mass Azithromycin Distribution #MMPMID32426812
Doan T; Hinterwirth A; Arzika AM; Worden L; Chen C; Zhong L; Oldenburg CE; Keenan JD; Lietman TM
Clin Infect Dis 2020[Nov]; 71 (16): 2282-2284 PMID32426812show ga
We evaluated the potential antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had received multiple rounds of mass drug administration. We found that the respiratory burden of non-severe acute respiratory syndrome coronaviruses was decreased with azithromycin distributions. Clinical Trials Registration. NCT02047981.